Scalp application of antioxidants improves scalp condition and reduces hair shedding in a 24-week randomized, double-blind, placebo-controlled clinical trial

被引:15
|
作者
Davis, Michael G. [1 ]
Piliang, Melissa P. [2 ,3 ]
Bergfeld, Wilma F. [2 ,3 ]
Caterino, Tamara L. [1 ]
Fisher, Brian K. [1 ]
Sacha, Jarek P. [1 ]
Carr, Gregory J. [1 ]
Moulton, Laura T. [1 ]
Whittenbarger, Deborah J. [1 ]
Schwartz, James R. [1 ]
机构
[1] Procter & Gamble Co, Mason, OH 45040 USA
[2] Cleveland Clin, Dept Dermatol, Cleveland, OH 44106 USA
[3] Cleveland Clin, Dept Pathol, Cleveland, OH 44106 USA
关键词
antioxidant; hair growth; hair loss; hair shedding; hair treatment; scalp; skin barrier; OXIDATIVE STRESS; ANDROGENETIC ALOPECIA; SEBORRHEIC DERMATITIS; PROTEIN OXIDATION; PYRITHIONE ZINC; DAMAGE; DISORDERS; MINOXIDIL; RADICALS; DANDRUFF;
D O I
10.1111/ics.12734
中图分类号
O69 [应用化学];
学科分类号
081704 ;
摘要
Objective Increasing hair fullness is a global unmet need for many men and women. An approach to the problem is to decrease hair fall or shedding by reducing scalp stratum corneum oxidation and barrier damage to increase hair retention. This study evaluated a combination of functional antioxidants and barrier-enhancing cosmetic ingredients to improve scalp condition thereby enabling stronger hair anchorage and longer retention. Methods Male and female subjects with normal scalp condition and self-perceived hair thinning participated in a 24-week, double-blind, placebo-controlled, randomized clinical study assessing either a regimen of treatment shampoo and leave-on treatment containing functional antioxidant and barrier-enhancing agents or an identical placebo chassis shampoo control. The functional ingredients were piroctone olamine, zinc pyrithione, zinc carbonate, niacinamide, panthenol and caffeine. At baseline and after 8, 16 and 24 weeks of product use, several measurements were taken: hair shedding, total hair count (by phototrichogram), hair samples, TEWL and evaluation of biomarkers of scalp and hair conditions. Subjects also completed self-assessment questionnaires. Results Statistically significant effects for functional ingredient-containing treatment regimen versus a placebo control shampoo formulation were observed for reduced hair shedding, increased total hair count, reduced TEWL and improvement in scalp biomarker values. Subjects also noticed these improvements assessed via self-assessment questionnaires. Conclusions These results establish that the use of functional antioxidant and barrier-enhancing agents to further improve scalp condition can enable a reduction in hair shedding and thus an increase in perceived hair fullness. The underlying improvements in scalp condition suggest the hair benefits were achieved as a result of improved scalp skin barrier and scalp condition leading to a viable preventative approach for hair thinning.
引用
收藏
页码:S14 / S25
页数:12
相关论文
共 50 条
  • [31] Moderate to severe plaque psoriasis with scalp involvement: A randomized, double-blind, placebo-controlled study of etanercept
    Bagel, Jerry
    Lynde, Charles
    Tyring, Stephen
    Kricorian, Gregory
    Shi, Yifei
    Klekotka, Paul
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2012, 67 (01) : 86 - 92
  • [32] Preincision 0.25% bupivacaine scalp infiltration and postcraniotomy pain - A randomized double-blind, placebo-controlled study
    Biswas, BK
    Bithal, PK
    JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY, 2003, 15 (03) : 234 - 239
  • [33] A double-blind, placebo-controlled trial of a ciclopirox olamine 1% shampoo for the treatment of scalp seborrheic dermatitis
    Vardy, DA
    Zvulunov, A
    Tchetov, T
    Biton, A
    Rosenman, D
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2000, 11 (02) : 73 - 77
  • [34] Vitamin E does not reduce symptoms of rheumatoid arthritis: A 24-week randomized, double-blind, placebo-controlled study.
    Boileau, N
    Blumberg, J
    Dallal, GE
    Golly, I
    Roubenoff, R
    ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S179 - S179
  • [35] A 24-Week, Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study of Ziritaxestat in Early Diffuse Cutaneous Systemic Sclerosis
    Khanna, Dinesh
    Denton, Christopher P.
    Furst, Daniel E.
    Mayes, Maureen D.
    Matucci-Cerinic, Marco
    Smith, Vanessa
    de Vries, Dick
    Ford, Paul
    Bauer, Yasmina
    Randall, Matthew J.
    Ebrahimpoor, Mitra
    Kupcsik, Laszlo
    Stiers, Pieter-Jan
    Deberdt, Liesbeth
    Prasad, Niyati
    Lim, Sharlene
    Pujuguet, Philippe
    Ahmed, Sohail
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 (08) : 1434 - 1444
  • [36] Anti-Interleukin 17A Monoclonal Antibody Secukinumab Reduces Signs and Symptoms of Psoriatic Arthritis in a 24-Week Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial
    McInnes, I.
    Sieper, J.
    Braun, J.
    Emery, Paul
    van der Heijde, D.
    Isaacs, J.
    Dahmen, G.
    Wollenhaupt, J.
    Schulze-Koops, H.
    Gsteiger, S.
    Bertolino, A.
    Hueber, W.
    Tak, P. P.
    ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S306 - S306
  • [37] A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Down syndrome and Alzheimer's disease - Pilot Study
    Prasher, VP
    Huxley, A
    Haque, MS
    INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2002, 17 (03) : 270 - 278
  • [38] Donepezil treatment of patients with severe Alzheimer's disease in a Japanese population: Results from a 24-week, double-blind, placebo-controlled, Randomized trial
    Homma, Akira
    Imai, Yukimichi
    Tago, Hisao
    Asada, Takashi
    Shigeta, Masahiro
    Iwamoto, Toshihiko
    Takita, Masashi
    Arimoto, Itaru
    Koma, Hiroshi
    Ohbayashi, Toshio
    DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2008, 25 (05) : 399 - 407
  • [39] Cardiovascular and Glycemic Benefits of Bexagliflozin as an Adjunct to Metformin for the Treatment of Type 2 Diabetes in Adults: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial
    Halvorsen, Yuan-Di C.
    Lock, John P.
    Freeman, Mason W.
    DIABETES, 2020, 69
  • [40] Agomelatine Prevents Relapse in Patients With Major Depressive Disorder Without Evidence of a Discontinuation Syndrome: A 24-Week Randomized, Double-Blind, Placebo-Controlled Trial
    Goodwin, Guy M.
    Emsey, Robin
    Rembry, Sandra
    Rouillon, Frederic
    JOURNAL OF CLINICAL PSYCHIATRY, 2009, 70 (08) : 1128 - 1137